Abbott Sees Atrasentan Market Opportunity In Less Advanced Prostate Cancer

Abbott sees a market opportunity for atrasentan in prostate cancer patients with less advanced disease based on the company's initial subset analysis of an unfavorable Phase III study for the endothelin-1 receptor antagonist